AMARIN CORP PLC\UK Sales Revenue, Goods, Net (Deprecated 2018-01-31)
AMARIN CORP PLC\UK (AMRN) reported Sales Revenue, Goods, Net (Deprecated 2018-01-31) of $43.78 million for the 3-month period ending 2018-03-31, per its 10-Q filed 2018-05-02.
Discontinued › Expense Statement › Operating Expenses
us-gaap:SalesRevenueGoodsNet · last filed 2018-05-02
- AMARIN CORP PLC\UK sales revenue, goods, net (deprecated 2018-01-31) for the quarter ending 2018-03-31 was $43.78M, a 27.47% increase year-over-year.
- AMARIN CORP PLC\UK sales revenue, goods, net (deprecated 2018-01-31) for the quarter ending 2017-12-31 was $53.48M, a 39.27% increase year-over-year.
- AMARIN CORP PLC\UK sales revenue, goods, net (deprecated 2018-01-31) for the quarter ending 2017-09-30 was $47.05M, a 45.04% increase year-over-year.
- AMARIN CORP PLC\UK sales revenue, goods, net (deprecated 2018-01-31) for the quarter ending 2017-06-30 was $44.95M, a 36.97% increase year-over-year.
- AMARIN CORP PLC\UK sales revenue, goods, net (deprecated 2018-01-31) for fiscal 2017 was $179.82M, a 39.44% increase from fiscal 2016.
- AMARIN CORP PLC\UK sales revenue, goods, net (deprecated 2018-01-31) for fiscal 2016 was $128.97M, a 59.24% increase from fiscal 2015.
- AMARIN CORP PLC\UK sales revenue, goods, net (deprecated 2018-01-31) for fiscal 2015 was $80.99M, a 49.42% increase from fiscal 2014.
- AMARIN CORP PLC\UK sales revenue, goods, net (deprecated 2018-01-31) for fiscal 2014 was $54.20M, a 105.69% increase from fiscal 2013.
| Period end | Sales Revenue, Goods, Net (Deprecated 2018-01-31) 3 month | Sales Revenue, Goods, Net (Deprecated 2018-01-31) 3 month as first filed | Sales Revenue, Goods, Net (Deprecated 2018-01-31) 6 month | Sales Revenue, Goods, Net (Deprecated 2018-01-31) 9 month | Sales Revenue, Goods, Net (Deprecated 2018-01-31) 12 month |
|---|---|---|---|---|---|
| 2018-03-31 | $43.78M 10-Q · filed 2018-05-02 | $97.26M derived: sum of 2 quarters · filed 2018-05-02 | $144.31M derived: sum of 3 quarters · filed 2018-05-02 | $189.26M derived: sum of 4 quarters · filed 2018-05-02 | |
| 2017-12-31 | $53.48M derived: 10-K 12 month − 10-Q 9 month · filed 2018-02-27 | $100.53M derived: sum of 2 quarters · filed 2018-02-27 | $145.48M derived: sum of 3 quarters · filed 2018-02-27 | $179.82M 10-K · filed 2018-02-27 | |
| 2017-09-30 | $47.05M 10-Q · filed 2017-11-01 | $92.00M derived: sum of 2 quarters · filed 2017-11-01 | $126.34M 10-Q · filed 2017-11-01 | $164.75M derived: sum of 4 quarters · filed 2018-05-02 | |
| 2017-06-30 | $44.95M 10-Q · filed 2017-08-02 | $79.29M 10-Q · filed 2017-08-02 | $117.69M derived: sum of 3 quarters · filed 2018-05-02 | $150.14M derived: sum of 4 quarters · filed 2018-05-02 | |
| 2017-03-31 | $34.34M 10-Q · filed 2018-05-02 | $72.75M derived: sum of 2 quarters · filed 2018-05-02 | $105.19M derived: sum of 3 quarters · filed 2018-05-02 | $138.00M derived: sum of 4 quarters · filed 2018-05-02 | |
| 2016-12-31 | $38.40M derived: 10-K 12 month − 10-Q 9 month · filed 2018-02-27 | $70.84M derived: sum of 2 quarters · filed 2018-02-27 | $103.66M derived: sum of 3 quarters · filed 2018-02-27 | $128.97M 10-K · filed 2018-02-27 | |
| 2016-09-30 | $32.44M 10-Q · filed 2017-11-01 | $65.26M derived: sum of 2 quarters · filed 2017-11-01 | $90.56M 10-Q · filed 2017-11-01 | $116.97M derived: sum of 4 quarters · filed 2018-02-27 | |
| 2016-06-30 | $32.81M 10-Q · filed 2017-08-02 | $58.12M 10-Q · filed 2017-08-02 | $84.52M derived: sum of 3 quarters · filed 2018-02-27 | $105.84M derived: sum of 4 quarters · filed 2018-02-27 | |
| 2016-03-31 | $25.31M 10-Q · filed 2017-05-03 | $51.71M derived: sum of 2 quarters · filed 2018-02-27 | $73.03M derived: sum of 3 quarters · filed 2018-02-27 | $90.74M derived: sum of 4 quarters · filed 2018-02-27 | |
| 2015-12-31 | $26.40M derived: 10-K 12 month − 10-Q 9 month · filed 2018-02-27 | $47.72M derived: sum of 2 quarters · filed 2018-02-27 | $65.43M derived: sum of 3 quarters · filed 2018-02-27 | $80.99M 10-K · filed 2018-02-27 | |
| 2015-09-30 | $21.32M 10-Q · filed 2016-11-03 | $39.03M derived: sum of 2 quarters · filed 2016-11-03 | $54.59M 10-Q · filed 2016-11-03 | $71.06M derived: sum of 4 quarters · filed 2017-03-01 | |
| 2015-06-30 | $17.71M 10-Q · filed 2016-08-04 | $33.27M 10-Q · filed 2016-08-04 | $49.74M derived: sum of 3 quarters · filed 2017-03-01 | $63.89M derived: sum of 4 quarters · filed 2017-03-01 | |
| 2015-03-31 | $15.56M 10-Q · filed 2016-05-05 | $32.04M derived: sum of 2 quarters · filed 2017-03-01 | $46.19M derived: sum of 3 quarters · filed 2017-03-01 | $58.79M derived: sum of 4 quarters · filed 2017-03-01 | |
| 2014-12-31 | $16.48M derived: 10-K 12 month − 10-Q 9 month · filed 2017-03-01 | $30.63M derived: sum of 2 quarters · filed 2017-03-01 | $43.23M derived: sum of 3 quarters · filed 2017-03-01 | $54.20M 10-K · filed 2017-03-01 | |
| 2014-09-30 | $14.15M 10-Q · filed 2015-11-04 | $26.75M derived: sum of 2 quarters · filed 2015-11-04 | $37.72M 10-Q · filed 2015-11-04 | ||
| 2014-06-30 | $12.61M 10-Q · filed 2015-08-06 | $23.57M 10-Q · filed 2015-08-06 | |||
| 2014-03-31 | $10.97M 10-Q · filed 2015-05-08 | $10.00M 10-Q · filed 2014-05-09 | |||
| 2013-12-31 | $26.35M 10-K · filed 2016-02-25 | ||||
| 2013-03-31 | $2.34M 10-Q · filed 2013-05-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Processa Pharmaceuticals, Inc. (PCSA) | United States | $0.005B | |
| Dermata Therapeutics, Inc. (DRMA) | United States | $0.005B | -0.62 |
| REVIVA PHARMACEUTICALS HOLDINGS, INC. (RVPH) | United States | $0.005B | |
| Xenetic Biosciences, Inc. (XBIO) | United States | $0.006B | |
| ProPhase Labs, Inc. (PRPH) | United States | $0.006B | -0.06 |
| Cadrenal Therapeutics, Inc. (CVKD) | United States | $0.004B | -0.90 |
| Lakewood-Amedex Biotherapeutics Inc. (LABT) | United States | $0.004B | |
| Pulmatrix, Inc. (PULM) | United States | $0.006B | |
| 60 DEGREES PHARMACEUTICALS, INC. (SXTP) | United States | $0.004B | -0.59 |
| Ernexa Therapeutics Inc. (ERNA) | United States | $0.006B |